| NASA2 study | p value versus placebo | SPACE2 study | p value versus placebo |
---|
Placebo | 38.2% | - | 39.8% | - |
Esomeprazole 20 mg | 28.3% | 0.04 | 30.7% | 0.07 |
Esomeprazole 40 mg | 24.3% | 0.004 | 28.4% | 0.05 |
- Kaplan-Meier life-table estimates of proportion of patients with relapse of pain, discomfort, or burning in the upper abdomen throughout 6 months of treatment with esomeprazole 20 mg, esomeprazole 40 mg, or placebo and log-rank comparisons for the individual studies. NASA, Nexium Anti-inflammatory Symptom Amelioration; SPACE, Symptom Prevention by Acid Control with Esomeprazole.